Long-term adherence to clinical therapy of overactive bladder
Overactive bladder (OAB) is a highly prevalent symptom syndrome, with considerable personal and health economic impact. Conventional management requires conservative interventions, including adherence to fluid advice and bladder training (1). Medications can then be used, with antimuscarinics forming the mainstay of drug interventions for many years. The recent introduction of a beta-3 agonist established a new drug class for the indication, with a differing side effect profile from the antimuscarinics. Beta-3 agonists do not affect the cholinergic receptors responsible for salivation, so problems of dry mouth symptoms are unusual with the first-in-class agent, mirabegron.